"Reduction of draining tunnels and abscesses is key for patients with HS because of the huge impact these lesions have on patients' lives," said Professor Steven Daveluy, M.D., Program Director Clinical Educator, Wayne State University. "These new data, showing high rates of reduction of these painful lesions to three years, demonstrate the sustained symptom relief bimekizumab provides and suggest the possibility of reducing the structural damage frequently seen with HS that can be so devastating for patients."
"These results for bimekizumab show meaningful improvements in inflammatory lesions and skin pain to three years, and offer a valuable perspective on its sustained efficacy for patients with HS," said Donatello Crocetta, Chief Medical Officer, UCB. "Our research presented at SHSA underscores UCB's commitment to providing long-term data addressing key clinical features of chronic inflammatory conditions with a high unmet need."
In a post-hoc analysis, of patients who had at least one draining tunnel at baseline (n=425), 48.2% (205/425) had none at one year, and 62.9% (183/291) at three years.2 In the same analysis of patients who had at least one abscess at baseline (n=381), 75.3% (287/381) had none at one year, and 83.5% (203/243) at three years. 2 In a second analysis of patients with no draining tunnels at baseline (n=131), 87.8% (115/131) still had none at one year, and 90.8% (69/76) at three years.3* In a third analysis, at baseline 10.0% (55/551) of patients reported no/mild skin pain, based on HSSQ skin pain item scores; at year one/three, the proportion of patients reporting no/mild skin pain increased to 51.7% (287/555) and 65.8% (237/360), respectively.4*
UCB will present six abstracts on BIMZELX in HS at the Symposium on Hidradenitis Suppurativa Advances (SHSA) 2025 congress in Nashville, Tennessee, October 31 to November 2, 2025. These data emphasize UCB's strength in providing rigorous, insightful clinical research, and meaningful solutions for this serious chronic disease.
*OC: Data are reported as observed case (OC). The data reported are from an observational, open-label study. Patients completing the 48-week BE HEARD I & II studies could enroll in BE HEARD EXT and receive open-label BIMZELX (BKZ) 320 mg every 2 weeks (Q2W) or Q4W based on HiSCR90 response averaged from Weeks 36, 40, and 44.6 Data are reported for patients randomized to BKZ from baseline in BE HEARD I & II who entered BE HEARD EXT (BKZ Total group, n=556) at Week 48. Only patients who entered the third year are included.2-5
The approved dosing regimen is BIMZELX 320mg Q2W to Week 16 and then 320mg Q4W thereafter.1 Results included patients receiving both Q2W and Q4W after Week 48. Per protocol, all patients who continued in the trial after Week 48 were subsequently switched to Q4W eventually by the end of year three. For safety outcomes, data are reported for patients who received one or more doses of BKZ across BE HEARD I & II and BE HEARD EXT (total of three years). The FDA approved dose of BIMZELX for adult patients with moderate-to-severe hidradenitis suppurativa is 320mg Q2W to Week 16, followed by Q4W.
About hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic, painful, and potentially debilitating inflammatory skin disease that is associated with systemic manifestations.7-8 The main symptoms are nodules abscesses, and pus discharging draining tunnels (or sinus tracts leading out of the skin), which can occur anywhere hair follicles are found, but is commonly seen in the armpits, groin, and buttocks.7-8 People with HS experience flare-ups of the disease as well as severe pain, which can have a major impact on quality of life.7-8 HS develops in early adulthood and affects approximately one percent of the population in most studied countries.
About BE HEARD trials
The efficacy and safety profile of BIMZELX were evaluated in adult patients with moderate-to severe hidradenitis suppurativa (HS) in two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (BE HEARD I and BE HEARD II).9 The two studies had a combined enrollment of 1,014 participants.9 In each study, patients were randomized 2:2:2:1 (initial [16 weeks]/maintenance [32 weeks]) to BIMZELX 320 mg every two weeks, four weeks, or a combination (BKZ Q2W/Q2W, BKZ Q2W/Q4W, BKZ Q4W/Q4W or placebo/BKZ Q2W).9 Receiving BKZ Q2W to Week 16, then Q4W thereafter is the approved dosing regimen (Q2W/Q4W) for the treatment of HS.
Patients who completed Week 48 could enroll in the open-label extension.6 Of 1,014 total patients, 556 patients randomized at baseline to BIMZELX in BE HEARD I and II completed Week 48 and entered the open-label extension study; 446 patients in the open-label extension study completed Week 96, 6 and 367 completed to Week 148.10
About BIMZELX® (bimekizumab-bkzx) in the U.S.
BIMZELX is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.1 Elevated levels of IL-17A and IL-17F are found in lesional psoriatic skin.1
Suicidal Ideation and Behavior
BIMZELX (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been definitively established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, instruct to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.
Infections
BIMZELX may increase the risk of infections, including serious infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.
Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.
Liver Biochemical Abnormalities
Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase, and bilirubin at baseline, periodically during treatment with BIMZELX, and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.
Inflammatory Bowel Disease
Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.
Immunizations
Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB).
